His post-doctoral training was done in Jordan Pober's laboratory at Yale University School of Medicine where he characterized signal transduction pathways in endothelial cells in response to inflammatory cytokines such as TNF and interferons. He led a group of scientists to demonstrate a novel strategy for antiangiogenic gene therapy. His major research interests include signal transduction of inflammatory cytokines, molecular control of angiogenesis, and plasmid-based gene delivery for treatment of vascular diseases. The research Dr. Min's lab aims to acquire is new knowledge relating to the molecular control of vascular endothelial functions during inflammation and angiogenesis. Inflammation involves endothelial activation and recruitment of circulating leukocytes at sites of local inflammation.
Angiogenesis involves endothelial proliferation, differentiation and migration.
It is now recognized that these two events are physiologically and pathologically related. On the other hand, angiogenesis is associated with inflammatory diseases such as atherosclerosis and rheumatoid arthritis. To separate good effects of a cytokine from its bad effects, we need to understand how each cytokine contributes to the process of repair. By dissecting signals from different cytokines and dissecting different signals from a single cytokine we hope to discover novel targets for gene therapy to treat inflammatory diseases such as atherosclerosis, and angiogenic diseases such as coronary artery disease and peripheral artery disease. She received her Ph.D. degree in molecular pharmacology from the University of Washington, Seattle in 1996.